These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. A Multicenter, Randomized, Double-Blind, Phase 2 Study of the Efficacy and Safety of Plazomicin Compared with Levofloxacin in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis. Connolly LE; Riddle V; Cebrik D; Armstrong ES; Miller LG Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29378708 [TBL] [Abstract][Full Text] [Related]
26. Comparative in vitro activity of plazomicin and older aminoglyosides against Enterobacterales isolates; prevalence of aminoglycoside modifying enzymes and 16S rRNA methyltransferases. Gür D; Hasdemir U; Çakar A; Çavuşoğlu İ; Çelik T; Aksu B; Diagn Microbiol Infect Dis; 2020 Aug; 97(4):115092. PubMed ID: 32569921 [TBL] [Abstract][Full Text] [Related]
27. Evaluation of the Bactericidal Activity of Plazomicin and Comparators against Multidrug-Resistant Enterobacteriaceae. Thwaites M; Hall D; Shinabarger D; Serio AW; Krause KM; Marra A; Pillar C Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866876 [TBL] [Abstract][Full Text] [Related]
31. Impact of co-existence of PMQR genes and QRDR mutations on fluoroquinolones resistance in Enterobacteriaceae strains isolated from community and hospital acquired UTIs. Kotb DN; Mahdy WK; Mahmoud MS; Khairy RMM BMC Infect Dis; 2019 Nov; 19(1):979. PubMed ID: 31752702 [TBL] [Abstract][Full Text] [Related]
32. Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece. Galani I; Souli M; Daikos GL; Chrysouli Z; Poulakou G; Psichogiou M; Panagea T; Argyropoulou A; Stefanou I; Plakias G; Giamarellou H; Petrikkos G J Chemother; 2012 Aug; 24(4):191-4. PubMed ID: 23040681 [TBL] [Abstract][Full Text] [Related]
33. Comparison of in vitro activities of plazomicin and other aminoglycosides against clinical isolates of Klebsiella pneumoniae and Escherichia coli. İnce G; Mirza HC; Üsküdar Güçlü A; Gümüş H; Erol Ç; Başustaoğlu A J Antimicrob Chemother; 2021 Nov; 76(12):3192-3196. PubMed ID: 34499728 [TBL] [Abstract][Full Text] [Related]
34. Pharmacodynamics of plazomicin and a comparator aminoglycoside, amikacin, studied in an in vitro pharmacokinetic model of infection. Noel AR; Attwood M; Bowker KE; Kim A; Krause KM; MacGowan AP Int J Antimicrob Agents; 2019 Nov; 54(5):626-632. PubMed ID: 31299297 [TBL] [Abstract][Full Text] [Related]
35. Association between the Presence of Aminoglycoside-Modifying Enzymes and In Vitro Activity of Gentamicin, Tobramycin, Amikacin, and Plazomicin against Klebsiella pneumoniae Carbapenemase- and Extended-Spectrum-β-Lactamase-Producing Enterobacter Species. Haidar G; Alkroud A; Cheng S; Churilla TM; Churilla BM; Shields RK; Doi Y; Clancy CJ; Nguyen MH Antimicrob Agents Chemother; 2016 Sep; 60(9):5208-14. PubMed ID: 27297487 [TBL] [Abstract][Full Text] [Related]
36. Expected plazomicin susceptibility in India based on the prevailing aminoglycoside resistance mechanisms in Gram-negative organisms derived from whole-genome sequencing. Pragasam AK; Jennifer SL; Solaimalai D; Muthuirulandi Sethuvel DP; Rachel T; Elangovan D; Vasudevan K; Gunasekaran K; Veeraraghavan B Indian J Med Microbiol; 2020; 38(3 & 4):313-318. PubMed ID: 33154241 [TBL] [Abstract][Full Text] [Related]
37. In vitro comparison of netilmicin, a semisynthetic derivative of sisomicin, and four other aminoglycoside antibiotics. Kabins SA; Nathan C; Cohen S Antimicrob Agents Chemother; 1976 Jul; 10(1):139-45. PubMed ID: 825021 [TBL] [Abstract][Full Text] [Related]
38. Activity of plazomicin against carbapenem-intermediate or -resistant Escherichia coli isolates from the United States and international sites in relation to clonal background, resistance genes, co-resistance, and region. Johnston BD; Thuras P; Porter SB; Anacker M; VonBank B; Snippes Vagnone P; Witwer M; Castanheira M; Johnson JR J Antimicrob Chemother; 2021 Jul; 76(8):2061-2070. PubMed ID: 34097032 [TBL] [Abstract][Full Text] [Related]
39. Plazomicin for the treatment of patients with complicated urinary tract infection. McCarthy MW Drugs Today (Barc); 2018 Sep; 54(9):513-518. PubMed ID: 30303492 [TBL] [Abstract][Full Text] [Related]
40. Can Plazomicin Alone or in Combination Be a Therapeutic Option against Carbapenem-Resistant Acinetobacter baumannii? García-Salguero C; Rodríguez-Avial I; Picazo JJ; Culebras E Antimicrob Agents Chemother; 2015 Oct; 59(10):5959-66. PubMed ID: 26169398 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]